Gilead Sciences, Inc. (NASDAQ:GILD) Shares Sold by Atwood & Palmer Inc.

Atwood & Palmer Inc. decreased its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 1.2% during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 345,067 shares of the biopharmaceutical company's stock after selling 4,189 shares during the period. Gilead Sciences comprises 2.7% of Atwood & Palmer Inc.'s portfolio, making the stock its 6th largest holding. Atwood & Palmer Inc.'s holdings in Gilead Sciences were worth $38,665,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. Newbridge Financial Services Group Inc. purchased a new stake in Gilead Sciences during the fourth quarter valued at $33,000. Annis Gardner Whiting Capital Advisors LLC increased its position in shares of Gilead Sciences by 158.8% during the 4th quarter. Annis Gardner Whiting Capital Advisors LLC now owns 352 shares of the biopharmaceutical company's stock valued at $33,000 after purchasing an additional 216 shares during the last quarter. Morton Brown Family Wealth LLC bought a new position in shares of Gilead Sciences in the 4th quarter worth approximately $35,000. Whipplewood Advisors LLC purchased a new position in shares of Gilead Sciences in the fourth quarter worth approximately $35,000. Finally, Synergy Investment Management LLC purchased a new position in shares of Gilead Sciences during the 4th quarter worth $40,000. Institutional investors own 83.67% of the company's stock.

Wall Street Analyst Weigh In

GILD has been the subject of a number of analyst reports. Piper Sandler increased their price objective on shares of Gilead Sciences from $105.00 to $110.00 and gave the stock an "overweight" rating in a research note on Wednesday, February 12th. Oppenheimer decreased their target price on shares of Gilead Sciences from $132.00 to $125.00 and set an "outperform" rating on the stock in a research report on Friday, April 25th. JPMorgan Chase & Co. raised their price target on Gilead Sciences from $120.00 to $130.00 and gave the stock an "overweight" rating in a research report on Thursday, March 27th. Royal Bank of Canada upped their target price on Gilead Sciences from $84.00 to $90.00 and gave the company a "sector perform" rating in a research note on Wednesday, February 12th. Finally, Morgan Stanley raised their price target on shares of Gilead Sciences from $130.00 to $135.00 and gave the stock an "overweight" rating in a research note on Friday, April 25th. Nine investment analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and three have assigned a strong buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $110.55.

Insiders Place Their Bets

In related news, CEO Daniel Patrick O'day sold 10,000 shares of the business's stock in a transaction on Friday, May 30th. The shares were sold at an average price of $110.42, for a total transaction of $1,104,200.00. Following the completion of the transaction, the chief executive officer now directly owns 620,268 shares in the company, valued at $68,489,992.56. The trade was a 1.59% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Johanna Mercier sold 28,000 shares of the stock in a transaction dated Thursday, May 22nd. The stock was sold at an average price of $107.52, for a total value of $3,010,560.00. Following the sale, the insider now directly owns 121,152 shares in the company, valued at $13,026,263.04. This represents a 18.77% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 43,000 shares of company stock valued at $4,630,310. Insiders own 0.27% of the company's stock.

Gilead Sciences Stock Down 2.6%

Shares of Gilead Sciences stock traded down $2.91 during trading on Tuesday, reaching $110.09. The company's stock had a trading volume of 8,870,755 shares, compared to its average volume of 7,749,499. Gilead Sciences, Inc. has a 1-year low of $62.69 and a 1-year high of $119.96. The company has a 50-day simple moving average of $105.41 and a two-hundred day simple moving average of $101.80. The company has a quick ratio of 1.20, a current ratio of 1.50 and a debt-to-equity ratio of 1.24. The company has a market cap of $136.94 billion, a price-to-earnings ratio of 297.54, a P/E/G ratio of 0.71 and a beta of 0.29.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last issued its quarterly earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.81 earnings per share for the quarter, topping the consensus estimate of $1.77 by $0.04. Gilead Sciences had a return on equity of 31.63% and a net margin of 1.67%. The business had revenue of $6.67 billion during the quarter, compared to the consensus estimate of $6.77 billion. During the same quarter last year, the company earned ($1.32) earnings per share. The company's quarterly revenue was down .3% on a year-over-year basis. As a group, equities analysts forecast that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, June 27th. Shareholders of record on Friday, June 13th will be paid a dividend of $0.79 per share. The ex-dividend date is Friday, June 13th. This represents a $3.16 dividend on an annualized basis and a yield of 2.87%. Gilead Sciences's payout ratio is 66.53%.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.